News Story: Full Text
Sponsored By
Cedars-Sinai Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website


Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://www.asco.org/ac/1,1003,_12-002489-00_18-002003-00_19-00103667-00_29-00A,00.asp?cat=CNS+Tumors&parent=Central+Nervous+System+Tumors&returnpid=2325&SubCat_ID=4

Posted on: 06/14/2003

Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme

Year: 2003 Printable Version

Abstract No: 451

Author(s): M. Bjeljac, F. Baumann and R. Bernays; University Hospital Zurich, Zurich, Switzerland

Abstract:

Purpose: This is a preliminary report of a non-randomised open-label phase II study of the use of the antiangiogenic agent thalidomide alone and in combination with the chemotherapeutic agent temozolomide for patients with Glioblastoma multiforme. The objectives are to determine whether these strategies can improve the median survival of patients with Glioblastoma multiforme and to evaluate toxicity. Microsurgical tumor extirpation and radiotherapy precede thalidomide and temozolomide therapy. Combination drug therapy is continued until disease progression, unacceptable toxicity, or for a maximum of one year. Patients are evaluated by magnetic resonance imaging and neurologically status for response and toxicity every 3 months.

Patients and Methods: Forty-four patients with Glioblastoma multiforme were evaluated for survival, time to tumor progression ( TTP ) and side effects. Nineteen patients (43% ) received thalidomide only ( T ), and 25 patients ( 57% ) had a combined therapy of thalidomide and temozolomide ( TT ). Median thalidomide dosage was 200mg/day. Median temozolomide dosage was 200mg/m2/day for five days, in monthly cycles. Neuroradiological outcomes were assessed using a semiquantitative grading system.

Results: Median survival was 103 weeks for TT-patients and 63 weeks for T-patients ( P< 0,01 ). Median TTP for the TT-group was 36 weeks and 17 weeks for the T-group ( P< 0,06 ). Neuroradiologically, 20 of 44 patients ( 45% ) showed stable disease, 22 ( 50% ) progressive disease, and two ( 5% ) tumor regression. Thalidomide and concurrent temozolomide were safe and well tolerated with mild to moderate toxicities.

Conclusion: This is the study investigating the tolerability and efficacy of continuous thalidomide treatment, alone and in combination with temozolomide, in patients with Glioblastoma multiforme. Thalidomide as a single agent did not show prolonged patient survival, whereas the combination of thalidomide and temozolomide appears to confer a survival advantage to selected patients.




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740